MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

25.77 -0.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

25.57

Max

26.12

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.8M 40M
Verkäufe	16M 200M
KGV Branchendurchschnitt	8.503 36.442
EPS	0.92
Gewinnspanne	19.839
Angestellte	268
EBITDA	3M 59M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+71.71% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	28. Okt. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-514M 1.5B
Vorheriger Eröffnungskurs	26.31
Vorheriger Schlusskurs	25.77

Nachrichtenstimmung

By Acuity

38%

62%

111 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2025, 18:13 UTC

Wichtige Markttreiber

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. Okt. 2025, 17:05 UTC

Wichtige Markttreiber

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17. Okt. 2025, 15:03 UTC

Wichtige Markttreiber

Obook Shares Sink Following Public Debut

17. Okt. 2025, 14:41 UTC

Wichtige Markttreiber

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17. Okt. 2025, 23:25 UTC

Akquisitionen, Fusionen, Übernahmen

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. Okt. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. Okt. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. Okt. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. Okt. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. Okt. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. Okt. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. Okt. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. Okt. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. Okt. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. Okt. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. Okt. 2025, 15:56 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. Okt. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Okt. 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17. Okt. 2025, 14:58 UTC

Market Talk

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17. Okt. 2025, 14:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Okt. 2025, 14:35 UTC

Market Talk

Ergebnisse

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

71.71% Vorteil

12-Monats-Prognose

Durchschnitt 44.56 USD 71.71%

Hoch 62 USD

Tief 31 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

111 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.